Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ichor initiates high dose melanoma vaccine trial
The vaccine, which was developed by Memorial Sloan-Kettering Cancer Center scientists, consists of DNA encoding a form of the tyrosinase protein. In the first stage of the trial,
The vaccine, which was developed by Memorial Sloan-Kettering Cancer Center scientists, consists of DNA encoding a form of the tyrosinase protein. In the first stage of the trial,
The agreement terms include a license fee based on the achievement of specific regulatory milestones and a sales-based royalty arrangement once regulatory clearances are established. Planned expenditures for
Teva argued that the FDA’s denial of Teva’s Citizen’s petition, seeking the relisting of US patent and restoration of Teva’s 180-day exclusivity for its pending abbreviated new drug
Pluristem has submitted a scientific package to the PEI. The package contains the results of a proof of concept study and preclinical study synopses utilizing PLX-PAD to support
The patent application was submitted under the patent cooperation treaty with 33 claims covering the device, related systems and methods of use. All 33 claims were allowed by
Niox Mino provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide, a validated method for assessing asthma-related airway inflammation. Niox Mino is said to be the
The orphan drug designation will entitle Mpex to a seven-year period of exclusive marketing rights for MP-376 for the orphan indication following the date of the drug’s marketing
The companies will evaluate and execute product development programs directed at immune stimulation and disease prevention in a variety of animal species. In addition, the agreement anticipates that
Under the terms of the partnership, Millipore will gain exclusive rights to distribute Guava’s non-clinical instrumentation within defined fields in North America, Europe and other countries in Asia.
Dainippon Sumitomo Pharma has a large product portfolio in the CNS area and has adopted a multifaceted research approach to target better treatments for psychiatric conditions, including schizophrenia,